Changes of the quality-of-life under the treatment of severe senile osteoporosis with teriparatide

Archives of Gerontology and Geriatrics

Volumn 49, Issue 1, 2009, Pages 35-38

  Maugeri, Domenico ^a   Russo, Enzo ^b   Luca, Salvatore ^a   Leotta, Carmelo ^a   Mamazza, Grazia ^a   Sorace, Rosaria ^a   Rizzotto, Maurizio ^a   Manuele, Sara ^a   Fiore, Valentina ^a   Taverna, Giuseppe ^a   Castiglia, Biagio ^a   Calitro, Michele ^c  

^a UNIVERSITY OF CATANIA   (Italy)

^b Unità Operativa Complessa di Geriatria e Lungodegenza di Patti   (Italy)

^c Unità Operativa Complessa di Geriatria   (Italy)

Author keywords

Osteoporotic fractures; QoL; QUALEFFO test; Severe senile osteoporosis; Teriparatide

Indexed keywords

ALENDRONIC ACID; CALCIUM; NONSTEROID ANTIINFLAMMATORY AGENT; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; VITAMIN D;

AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; SENILE OSTEOPOROSIS; SPINE MALFORMATION; STRUCTURED QUESTIONNAIRE;

AGED; BODY MASS INDEX; BONE DENSITY CONSERVATION AGENTS; FEMALE; HUMANS; MALE; OSTEOPOROSIS; QUALITY OF LIFE; TERIPARATIDE;

ESCHERICHIA COLI;

EID: 67349265130     PISSN: 01674943     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.archger.2008.04.008     Document Type: Article

References (17)

1. Adami S., Isaia G., Luisetto G., Minisola S., Sinigaglia L., Gentilella R., Agnusdei D., Iori N., Nuti R., and the ICARO Study Group. Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO Study. J. Bone Miner. Res. 21 (2006) 1565-1570
2. Bilezikian J.P., and Kurland E.S. Therapy of male osteoporosis with parathyroid hormone. Calcif. Tissue Int. 69 (2001) 248-251
3. Boonen S., Marin F., Mellstrom D., Xie L., Desaiah D., Krege J.H., and Rosen C.J. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J. Am. Geriatr. Soc. 54 (2006) 782-789
4. Brenneman S.K., Barrett-Connor E., Sajjan S., Markson L.E., and Siris E.S. Impact of recent fracture on heath-related quality of life in postmenopausal women. J. Bone Miner. Res. 21 (2006) 809-816
5. Cooper, C., Jakob, F., Chinn, C., Martin-Mola, E., Fardellone, P., Adami, S., Thalassinos, N.C., Melo-Gomes, J., Torgerson, D., Gibson, A., Marin, F., 2007. Fracture incidence and changes in quality of life in women with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO). Osteoporos. Int. 2007. October 30 (Epub ahead of print).
6. Dempster D.W., Cosman F., Kurland E.S., Zhou H., Nieves J., Woelfert L., Shane E., Plavetić K., Müller R., Bilezikian J., and Lindsay R. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J. Bone Miner. Res. 16 (1991) 1846-1853
7. Gold D.T., and Silverman S.L. Do estrogen or selective estrogen receptor modulators improve quality of life for women with postmenopausal osteoporosis?. Curr. Osteoporos. Rep. 5 (2007) 3-7
8. Jonsson B., Kanis J., Dawson A., Oden A., and Johnell O. Effect and offset of treatment for hip fracture on health outcomes. Osteoporos. Int. 10 (1999) 193-199
9. Lips P., and Van Schoor N.M. Quality of life in patients with osteoporosis. Osteoporos. Int. 16 (2005) 447-455
10. Lips P., Cooper C., Agnusdei D., Caulin F., Egger P., Johnell O., Kanis J.A., Kellingray S., Leplege A., Liberman U.A., McCloskey E., Minne H., Reeve J., Reginster J.Y., Scholz M., Todd C., Dde Vernejoul M.C., and Wiklund I. Quality of life in patients with vertebral fractures: validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO) Working Party for Quality of Life of the European Foundation for Osteoporosis. Osteoporos. Int. 10 (1999) 150-160
11. Manuele S., Sorbello L., Puglisi N., Grasso S., La Malfa L., D'Urbino G., Rizzotto M., Strano S., and Maugeri D. The teriparatide in the treatment of the severe senile osteoporosis. Arch. Gerontol. Geriatr. 44 Suppl. 1 (2007) 249-258
12. Marcinkowska M., Wawrzyniak A., Horst-Sikorska W., and Burchardt W. Quality of life in patients with hip bone fractures. Pol. Merkur Lekarski 21 (2006) 44-49 (in Polish)
13. Marquis P., Roux C., De la Loge C., Diaz-Curiel M., Cormier C., Isaia G., Badurski J., Wark J., and Meunier P.J. Strontium ranelate prevents quality of life impairment in post-menopausal women with established vertebral osteoporosis. Osteporos. Int. 19 (2007) 503-510
14. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., Hodsman A.B., Eriksen E.F., Ish-Shalom S., Genant H.K., Wang O., and Mitlak B.H. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New Engl. J. Med. 344 (2001) 1434-1441
15. Rubin M.R., Cosman F., Lindsay F., and Bilezikian J.P. The anabolic effects of parathyroid hormone. Osteoporos. Int. 13 (2002) 267-277
16. Salaffi F., Cimmino M.A., Malavolta N., Carotti M., Di Matteo M., Scendoni P., Grassi W., and Italian Multicentre Osteoporotic Fracture Study Group. The burden of prevalent fractures on health-related quality of life in postmenopausal women with osteoporosis: the IMOF study. J. Rheumatol. 34 (2007) 1551-1560
17. Silverman S.L., Shen W., Minshall M.E., Xie S., and Moses K.H. Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the multiple outcomes of Raloxifene evaluation (MORE) study. J. Rheumatol. 34 (2007) 140-144